FLT3 mutations are also among the kinase-activating lesions identified in Philadelphia chromosome–like (Ph-like) ALL, a high-risk subtype characterized by diverse genetic alterations activating tyrosine kinase signaling [31]. The gene discussed is FLT3; the disease is acute lymphoblastic leukemia.